Adverse outcomes in patients with heart failure admitted for COVID‑19 in association with the use of renin-angiotensin‑aldosterone system inhibitors

Pol Arch Intern Med. 2022 Jan 28;132(1):16126. doi: 10.20452/pamw.16126. Epub 2021 Oct 22.
No abstract available

MeSH terms

  • Angiotensin Receptor Antagonists / adverse effects
  • COVID-19*
  • Heart Failure* / drug therapy
  • Humans
  • Renin-Angiotensin System
  • SARS-CoV-2

Substances

  • Angiotensin Receptor Antagonists